Health Care & Life Sciences » Pharmaceuticals | RaQualia Pharma Inc.

RaQualia Pharma Inc. | Income Statement

Fiscal year is January-December. All values JPY Millions.
2013
2014
2015
2016
2017
Sales/Revenue
228
154
146
705
1,419
Cost of Goods Sold (COGS) incl. D&A
68
24
53
195
234
Gross Income
160
130
92
510
1,185
SG&A Expense
2,298
2,314
1,957
1,270
1,336
EBIT
2,138
2,184
1,865
760
150
Unusual Expense
83
44
134
8
2
Non Operating Income/Expense
1,117
1,575
68
36
54
Interest Expense
-
13
-
-
-
Pretax Income
1,102
632
1,848
723
60
Income Tax
6
7
6
5
2
Consolidated Net Income
1,108
639
1,854
728
58
Net Income
1,108
639
1,854
728
58
Net Income After Extraordinaries
1,108
639
1,854
728
58
Net Income Available to Common
1,108
639
1,854
728
58
EPS (Basic)
82.70
45.70
116.45
38.80
2.99
Basic Shares Outstanding
13
14
16
19
19
EPS (Diluted)
82.70
45.70
116.45
38.80
2.99
Diluted Shares Outstanding
13
14
16
19
19
EBITDA
2,070
2,162
1,811
680
65
Non-Operating Interest Income
1
34
82
65
39

About RaQualia Pharma

View Profile
Address
Daiwa Meieki Building, 8/F
Nagoya Aichi 450
Japan
Employees -
Website http://www.raqualia.co.jp
Updated 09/14/2018
RaQualia Pharma, Inc. engages in a research and development of pharmaceuticals. Its medicines focus on pain, gastrointestinal, auto-immune diseases, inflammation, cancer, and Alzheimer's. Its products include Anidulafungin, Dalbavancin, Ziprasidone, 5-HT4 Partial Agonist, and 5-HT2B Antagonist.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.